Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 1;21(7-9):27-47.
eCollection 2024 Jul-Sep.

Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review

Waguih William IsHak  1   2 , Ashley Meyer  3 , Luiza Freire  4 , Jayant Totlani  5 , Nathalie Murphy  1 , Sabrina Renteria  1 , Mohamed Salem  1 , Tiffany Chang  1 , Rasha Abdelsalam  1 , Rida Khan  1 , Thomas Chandy  6 , Thomas Parrish  1 , Drew Hirsch  1 , Bhumika Patel  5 , Alexander J Steiner  7 , Sarah Kim  1 , Rebecca Hedrick  1 , Robert N Pechnick  5 , Itai Danovitch  1
Affiliations
Review

Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review

Waguih William IsHak et al. Innov Clin Neurosci. .

Abstract

Objective: This systematic review provides an overview of psychiatric medications in the late stages of development (Phase III clinical trials) as of June 1, 2024. It details the mechanisms of action, efficacy, dosing, and adverse effects of these medications.

Methods: We searched the PubMed database for Phase III studies of psychiatric medications published until June 1, 2024, using the keywords "psychiatric" OR "psychopharm*" AND "medic*" OR "pharm*". Our review encompassed medications currently undergoing Phase III clinical trials and those that have completed Phase III but are awaiting approval from the United States Food and Drug Administration (FDA). We independently analyzed the identified studies and reached a consensus on the medications to be included in this systematic review.

Results: As of June 1, 2024, a total of 89 pipeline drug trials were identified, including nine for schizophrenia, five for bipolar disorders, 25 for depressive disorders, 11 for anxiety disorders, five for post-traumatic stress disorder (PTSD), one for obsessive compulsive disorder (OCD), two for eating disorders, two for sleep-wake disorders, three for sexual dysfunctions, one for substance-related and addictive disorders, 22 for neurocognitive disorders, and three for neurodevelopmental disorders, specifically attention deficit hyperactivity disorder (ADHD).

Conclusion: The psychiatric medications in the pipeline as of June 1, 2024, demonstrate significant promise in treating psychiatric disorders.

Keywords: FDA; Phase III clinical trials; Psychiatric medications; anxiety; bipolar disorder; depression; psychiatric disorders; schizophrenia.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURES: The authors have no conflicts of interest relevant to the content of this article.

References

    1. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fda-d... United States Food and Drug Administration. FDA drug approval process infographic (vertical). Current as of 26 Feb 2016. Accessed 1 May 2024.
    1. Pahwa M, Sleem A, Elsayed OH et al. New antipsychotic medications in the last decade. Curr Psychiatry Rep. 2021;23(12):87. - PubMed
    1. Tsapakis EM, Diakaki K, Miliaras A, Fountoulakis KN. Novel compounds in the treatment of schizophrenia-a selective review. Brain Sci. 2023;13(8):1193. - PMC - PubMed
    1. Greenwood LM, Leung S, Michie PT et al. The effects of glycine on auditory mismatch negativity in schizophrenia. Schizophr Res. 2018;191:61–69. - PubMed
    1. Kantrowitz JT, Epstein ML, Lee M et al. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: correlation with symptoms. Schizophr Res. 2018;191:70–79. - PubMed